Anaphylaxis in Public Health

dc.contributor.authorCmorej, Patrik Christian
dc.contributor.authorNesvadba, Marcel
dc.contributor.authorMamova, Alexandra
dc.contributor.authorBabeľa, Róbert
dc.contributor.authorPeřan, David
dc.contributor.authorPekara, Jaroslav
dc.contributor.authorKohlová, Alena
dc.contributor.authorBures, Petr
dc.contributor.authorTrpišovský, Jan
dc.contributor.authorFleischmann, Otakar
dc.contributor.authorPfefferová, Eva
dc.date.accessioned2021-03-22T11:00:18Z
dc.date.available2021-03-22T11:00:18Z
dc.date.issued2019
dc.description.abstract-translatedThe increasing number of patients with anaphylactic reactions is a modern challenge for healthcare professionals in clinical practice and public health professionals. It remains difficult to determine the prevalence or incidence of anaphylaxis in the population due to the long absence of a onsensus definition, the fact that analyses are performed on various population groups and the use of different data collection methodologies. In the United States, anaphylaxis mortality ranges from 0.63 to 0.76 cases per million inhabitants, with 58% of these deaths due to drug anaphylaxis. The risk factors for anaphylaxis are ramipril and metoprolol use, which is common in patients with cardiovascular disease. Also, a higher level of gliadin following excess gluten intake is associated with a higher incidence of anaphylaxis. Drugs, food and insect stings have long been known as anaphylaxis nductors. In diagnosis, determination of serum tryptase concentration is used. In patients with normal tryptase concentration, it is appropriate to screen other inflammatory mediators. The authors of this article present new findings on anaphylaxis in the literature and recommended practices of professional societies in the context of public health.en
dc.format8 s.cs
dc.format.mimetypeapplication/pdf
dc.identifier.citationCMOREJ, PCH. NESVADBA, M. MAMOVA, A. BABEĽA, R. PEŘAN, D. PEKARA, J. KOHLOVÁ, A. BURES, P. TRPIŠOVSKÝ, J. FLEISCHMANN, O. PFEFFEROVÁ, E. Anaphylaxis in Public Health. Neuroendocrinology Letters, 2019, roč. 40, č. 1, s. 3-10. ISSN 0172-780X.cs
dc.identifier.issn0172-780X
dc.identifier.obd43929298
dc.identifier.uri2-s2.0-85078038462
dc.identifier.urihttp://hdl.handle.net/11025/43008
dc.language.isoenen
dc.publisherMaghira and Maas Publicationsen
dc.relation.ispartofseriesNeuroendocrinology Lettersen
dc.rightsPlný text není přístupný.cs
dc.rights© Maghira and Maas Publicationsen
dc.rights.accessclosedAccessen
dc.subjectanafylaxecs
dc.subjecthistamincs
dc.subjectveřejné zdravícs
dc.subjecttryptázacs
dc.subject.translatedanaphylaxisen
dc.subject.translatedhistamineen
dc.subject.translatedpublic healthen
dc.subject.translatedtryptaseen
dc.titleAnaphylaxis in Public Healthen
dc.title.alternativeAnafylaxe ve veřejném zdravícs
dc.typečlánekcs
dc.typearticleen
dc.type.statusPeer-revieweden
dc.type.versionpublishedVersionen

Files